 Leonard Seibold
Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 36 | 2025 | 234 | 8.770 |
Why?
| | Intraocular Pressure | 47 | 2025 | 305 | 7.690 |
Why?
| | Glaucoma, Open-Angle | 20 | 2023 | 103 | 6.470 |
Why?
| | Phacoemulsification | 14 | 2025 | 122 | 4.610 |
Why?
| | Trabeculectomy | 16 | 2025 | 72 | 4.450 |
Why?
| | Cataract | 10 | 2023 | 213 | 2.740 |
Why?
| | Ocular Hypertension | 7 | 2022 | 67 | 2.600 |
Why?
| | Glaucoma Drainage Implants | 10 | 2024 | 46 | 2.370 |
Why?
| | Tonometry, Ocular | 23 | 2025 | 95 | 2.200 |
Why?
| | Visual Acuity | 13 | 2025 | 348 | 2.120 |
Why?
| | Laser Coagulation | 4 | 2025 | 68 | 1.550 |
Why?
| | Ciliary Body | 3 | 2025 | 39 | 1.540 |
Why?
| | Pilocarpine | 2 | 2025 | 15 | 1.520 |
Why?
| | Trabecular Meshwork | 7 | 2019 | 79 | 1.510 |
Why?
| | Endoscopy | 3 | 2025 | 318 | 1.270 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 17 | 1.250 |
Why?
| | Ophthalmology | 4 | 2023 | 86 | 1.110 |
Why?
| | Cataract Extraction | 5 | 2020 | 98 | 1.090 |
Why?
| | Laser Therapy | 3 | 2018 | 130 | 1.050 |
Why?
| | Ophthalmic Solutions | 6 | 2018 | 75 | 0.870 |
Why?
| | Filtering Surgery | 6 | 2016 | 22 | 0.850 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 487 | 0.830 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 59 | 0.810 |
Why?
| | Retinal Ganglion Cells | 3 | 2025 | 110 | 0.740 |
Why?
| | Nerve Fibers | 2 | 2012 | 96 | 0.710 |
Why?
| | Perception | 3 | 2021 | 359 | 0.700 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 213 | 0.650 |
Why?
| | Stents | 4 | 2021 | 527 | 0.640 |
Why?
| | Legislation, Drug | 1 | 2020 | 80 | 0.640 |
Why?
| | Postoperative Period | 7 | 2025 | 342 | 0.630 |
Why?
| | Burnout, Professional | 2 | 2025 | 440 | 0.630 |
Why?
| | Specialization | 1 | 2020 | 143 | 0.620 |
Why?
| | Retrospective Studies | 23 | 2025 | 15504 | 0.620 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 19 | 0.610 |
Why?
| | Medical Marijuana | 1 | 2020 | 117 | 0.580 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7585 | 0.570 |
Why?
| | Angiogenesis Inhibitors | 5 | 2020 | 226 | 0.570 |
Why?
| | Humans | 65 | 2025 | 136765 | 0.550 |
Why?
| | Aged | 21 | 2025 | 23794 | 0.550 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 10 | 0.540 |
Why?
| | Thiazines | 1 | 2017 | 10 | 0.540 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.530 |
Why?
| | Marijuana Smoking | 1 | 2020 | 249 | 0.530 |
Why?
| | Marijuana Use | 1 | 2020 | 203 | 0.520 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 26 | 0.510 |
Why?
| | Prospective Studies | 11 | 2021 | 7572 | 0.510 |
Why?
| | Sulfonamides | 2 | 2017 | 513 | 0.500 |
Why?
| | Corneal Diseases | 1 | 2016 | 34 | 0.490 |
Why?
| | Endophthalmitis | 1 | 2016 | 29 | 0.490 |
Why?
| | Vision Disorders | 3 | 2025 | 141 | 0.480 |
Why?
| | Middle Aged | 22 | 2025 | 33228 | 0.480 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2024 | 179 | 0.470 |
Why?
| | Circadian Rhythm | 2 | 2023 | 469 | 0.470 |
Why?
| | Treatment Outcome | 14 | 2025 | 10745 | 0.430 |
Why?
| | Ocular Hypotension | 3 | 2022 | 10 | 0.430 |
Why?
| | Cloprostenol | 1 | 2013 | 13 | 0.430 |
Why?
| | Physicians | 1 | 2022 | 907 | 0.410 |
Why?
| | Prosthesis Implantation | 4 | 2022 | 153 | 0.410 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5106 | 0.410 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1430 | 0.410 |
Why?
| | Male | 28 | 2025 | 67311 | 0.400 |
Why?
| | Female | 29 | 2025 | 72795 | 0.400 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 15 | 0.390 |
Why?
| | Visual Fields | 2 | 2025 | 90 | 0.390 |
Why?
| | Drug Combinations | 3 | 2020 | 343 | 0.390 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.350 |
Why?
| | Wound Healing | 2 | 2012 | 328 | 0.340 |
Why?
| | Stainless Steel | 1 | 2010 | 20 | 0.340 |
Why?
| | Blood Pressure | 2 | 2017 | 1774 | 0.340 |
Why?
| | Optic Disk | 1 | 2010 | 44 | 0.330 |
Why?
| | Contact Lenses | 2 | 2020 | 9 | 0.320 |
Why?
| | Uveitis | 2 | 2022 | 134 | 0.320 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2122 | 0.300 |
Why?
| | Adult | 17 | 2025 | 37631 | 0.290 |
Why?
| | Prednisolone | 2 | 2020 | 82 | 0.290 |
Why?
| | Software | 1 | 2012 | 665 | 0.270 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3265 | 0.240 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.240 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 16 | 0.240 |
Why?
| | Optometry | 1 | 2025 | 8 | 0.240 |
Why?
| | Optometrists | 1 | 2025 | 7 | 0.240 |
Why?
| | Visual Pathways | 1 | 2025 | 55 | 0.230 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5423 | 0.230 |
Why?
| | Optic Nerve Diseases | 1 | 2025 | 38 | 0.230 |
Why?
| | Sleep | 2 | 2023 | 753 | 0.230 |
Why?
| | Alkylating Agents | 2 | 2016 | 24 | 0.230 |
Why?
| | Postoperative Care | 2 | 2025 | 261 | 0.220 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.220 |
Why?
| | Glucocorticoids | 2 | 2020 | 593 | 0.210 |
Why?
| | Macular Edema | 1 | 2023 | 43 | 0.200 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5742 | 0.200 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 82 | 0.190 |
Why?
| | Communication Barriers | 1 | 2023 | 104 | 0.190 |
Why?
| | Diabetic Retinopathy | 1 | 2023 | 189 | 0.180 |
Why?
| | Heart Rate | 2 | 2017 | 820 | 0.180 |
Why?
| | Manometry | 1 | 2021 | 95 | 0.180 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.170 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.170 |
Why?
| | Gonioscopy | 1 | 2020 | 7 | 0.170 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 15 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 29 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 402 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 543 | 0.170 |
Why?
| | Amyloidosis | 1 | 2020 | 42 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 39 | 0.170 |
Why?
| | Language | 1 | 2023 | 292 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2023 | 283 | 0.160 |
Why?
| | Eye Diseases | 1 | 2020 | 87 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 91 | 0.160 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 412 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 3555 | 0.150 |
Why?
| | Intraoperative Complications | 1 | 2020 | 138 | 0.150 |
Why?
| | United States | 5 | 2025 | 14690 | 0.150 |
Why?
| | Preoperative Period | 1 | 2019 | 129 | 0.150 |
Why?
| | Mitomycin | 2 | 2016 | 34 | 0.150 |
Why?
| | Biosensing Techniques | 1 | 2020 | 122 | 0.150 |
Why?
| | Young Adult | 6 | 2025 | 13127 | 0.150 |
Why?
| | Axial Length, Eye | 1 | 2018 | 15 | 0.150 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.150 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.150 |
Why?
| | Pseudophakia | 1 | 2018 | 12 | 0.150 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 18 | 0.140 |
Why?
| | Refraction, Ocular | 1 | 2018 | 37 | 0.140 |
Why?
| | Time Factors | 2 | 2019 | 6808 | 0.140 |
Why?
| | Intravitreal Injections | 4 | 2020 | 56 | 0.130 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 17 | 0.130 |
Why?
| | Equipment Design | 1 | 2018 | 521 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2023 | 649 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2016 | 51 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 362 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 698 | 0.120 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 12 | 0.120 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 108 | 0.120 |
Why?
| | Drug Packaging | 1 | 2015 | 45 | 0.120 |
Why?
| | Device Removal | 1 | 2016 | 136 | 0.110 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 58 | 0.110 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 24 | 0.110 |
Why?
| | Travoprost | 1 | 2013 | 13 | 0.110 |
Why?
| | Patient Preference | 1 | 2016 | 190 | 0.110 |
Why?
| | Antimetabolites | 1 | 2012 | 23 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 664 | 0.100 |
Why?
| | Quality of Life | 1 | 2024 | 2878 | 0.100 |
Why?
| | Anterior Chamber | 1 | 2012 | 22 | 0.100 |
Why?
| | Conjunctiva | 1 | 2012 | 51 | 0.090 |
Why?
| | Blister | 1 | 2012 | 41 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 851 | 0.090 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 230 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 466 | 0.090 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 25 | 0.090 |
Why?
| | Equipment Safety | 1 | 2010 | 37 | 0.080 |
Why?
| | Torque | 1 | 2010 | 83 | 0.080 |
Why?
| | Dexamethasone | 1 | 2012 | 368 | 0.080 |
Why?
| | Tissue Donors | 1 | 2012 | 417 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1062 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1116 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2518 | 0.080 |
Why?
| | Reference Values | 1 | 2010 | 816 | 0.080 |
Why?
| | Cohort Studies | 1 | 2019 | 5701 | 0.070 |
Why?
| | Adolescent | 4 | 2020 | 21382 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 889 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2835 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1797 | 0.060 |
Why?
| | Geniculate Bodies | 1 | 2025 | 20 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 149 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 4191 | 0.060 |
Why?
| | Sickness Impact Profile | 1 | 2024 | 56 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2023 | 118 | 0.050 |
Why?
| | Rabbits | 2 | 2012 | 792 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2024 | 656 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 311 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2021 | 2639 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 539 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 40 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2710 | 0.040 |
Why?
| | Reoperation | 1 | 2020 | 573 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3432 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 178 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 179 | 0.030 |
Why?
| | Microscopy | 1 | 2018 | 145 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 551 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 95 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 267 | 0.030 |
Why?
| | Iris | 1 | 2013 | 19 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1692 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2750 | 0.020 |
Why?
| | Goblet Cells | 1 | 2012 | 22 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 507 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1612 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4013 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 301 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 180 | 0.020 |
Why?
| | Collagen | 1 | 2012 | 446 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2052 | 0.020 |
Why?
| | Animals | 3 | 2012 | 36847 | 0.010 |
Why?
| | Child | 1 | 2020 | 21819 | 0.010 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|